Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
HEДокторантска мрежа2022–2026

NADIS · NAD+ International Scientist-training

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2022-11-01 → 2026-10-31
Финансиране от ЕС
2 530 832 €
Участници
20
Схема
HORIZON-TMA-MSCA-DN

Линиите свързват координатора с партньорите.

Накратко на български

Молекулата NAD+ влияе върху енергията на тялото и връзката ѝ с болести като диабет и Алцхаймер. Разбирането на нейните нива помага за разработването на нови терапии за подобряване на здравето при стареене.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

NAD+ International Scientist-training

Nicotinamide adenine dinucleotide (NAD+) is a molecule that plays a vital role in the body’s energy production and many other functions. When cells run low on NAD+, it can lead to various diseases, including diabetes mellitus, neurodegenerative disorders, and infertility. On the flip side, increasing NAD+ levels might help prevent or treat these conditions. Research has uncovered important links between NAD+ and diseases like diabetes, Alzheimer’s, and even how long we live. Scientists are also looking at how lifestyle choices, nutrition, and medications can affect NAD+ levels to improve health and aging. However, there is still much we do not know, such as how NAD+ levels change throughout life, how their imbalance leads to disease, and which methods for boosting NAD+ are best for treating different conditions. The NADIS research group aims to fill these gaps by training new scientists to use advanced tools to study NAD+ and its role in health and disease. The potential scientific and societal impact of advancing our understanding of NAD+ is significant. By uncovering how NAD+ affects metabolism and disease, we expect to pave the way for new treatments for a wide range of age-related diseases. This could not only improve the quality of life for millions of people but also reduce healthcare costs associated with chronic and age-related diseases. Furthermore, developing NAD+-based therapies could promote healthier aging and extend lifespans, benefiting society as a whole by enhancing well-being in older populations and potentially transforming public health strategies. Finally, the knowledge gained through this research could also drive innovation in nutrition, pharmaceuticals, and lifestyle interventions, creating new opportunities for economic growth.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and the limiting substrate of key metabolic enzymes. The constellation of cellular functions in which NAD+ is involved makes its availability critical for cell survival, and its depletion is a leading factor in a number of diseases in humans, ranging from rare inherited defects to more common multifactorial, often age-related, complications, including type 2 diabetes, neurodegenerative diseases and female infertility. In contrast, NAD+-repletion strategies, such as administration of NAD+ precursors, may be effective in preventing or ameliorating the outcomes of these complications. NADIS partners have made pivotal discoveries in the field of NAD+ biology. First, by discovering novel mechanisms linking NAD+ metabolism to prevalent diseases such as type 2 diabetes, cancer cachexia, Alzheimer’s, Parkinson’s, or rare inherited mitochondrial disease, and to lifespan regulation. Second, by identifying lifestyle, nutritional, and drug interventions that target NAD+ metabolic pathways to combat such diseases and promote healthy aging. Despite these recent advances, there are still major gaps in our current knowledge in regard to (1) how NAD+ homeostasis is regulated at different stages in life, (2) how its imbalance leads to disease at a systemic level and (3) which NAD+ repletion strategy is the most suitable to prevent or treat specific diseases. It is the ambition of the NADIS consortium to fill these gaps by training the new generation of Early Stage Researchers (ESRs) on how to apply state-of-the-art tools to study the interconnection between metabolic cofactors, such as NAD+, and metabolic health at different levels, and to provide them with an interdisciplinary and intersectoral training programme that significantly increases their career perspectives and allow them to become future leaders in the field of translational metabolism.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз